Seoul Economic Daily EnglishCodex · 实盘不做把握 3/10
北京时间·🕒 发布 15:15:48时区推断·⟳ 抓取 15:53:01·⚡ 决策 07-14 16:10:04 +17m03s·105.1 天前
韩国多家公司披露临床、利润、合同、分红和再融资事项
该条是多家公司公告摘要合集，事件性质混杂，缺少逐家公司公告原文、金额口径和预期差。
📄 原文Seoul Economic Daily English↗ 原文
Corporate Disclosures
▲Celltrion (068270.KS) = Filed for a change to its European Phase 3 trial of a Darzalex biosimilar ▲Hanmi Semiconductor…
不做 Hanmi Semiconductor（042700.KS）
业绩摘要只给同比+51%，缺少绝对利润和一致预期差，无法确认超预期，不追。
不做 Celltrion（068270.KS）
临床试验变更申请方向不明，未披露关键疗效、监管或商业化增量，当前不做。
不做 KT（030200.KS）
600韩元分红和3109股库存股处置规模有限，缺少短期重定价催化。
不做 CMES Robotics（475400.KQ）
供应合同未披露金额、毛利和收入占比，无法做订单量级判断。
不做 ST Pharm（000760.KQ）
二期临床结果摘要缺少疗效、安全性和下一步监管路径，方向不足。
不做 TLB（237690.KQ）
1331亿韩元配股为稀释性融资，看空方向但默认不开空；可考虑降低相关多头敞口。
另有 1 腿,见展开详情。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
其余 1 腿
不做 FutureChem（237690.KS）
6570韩元发行价对应再融资事项，偏稀释但缺少强空催化和借券确认，不做空。
研究档案
🔎 新鲜度:最早出现 2026-07-14 · 扩散 low · price-in 风险 medium ↗
关键理由
- 该条是多家公司公告摘要合集，事件性质混杂，缺少逐家公司公告原文、金额口径和预期差。
- Hanmi Semiconductor二季度初步经营利润同比增51%偏正面，但未给出绝对利润、市场一致预期或是否超预期。
- TLB 1331亿韩元配股和FutureChem 6570韩元发行价偏融资稀释信息，默认不反手做多。
主要风险
- 部分合同或临床事项若公告原文显示金额重大、结果显著优于预期，可能需要单条重新评估。
原文全文
展开原文 · 1,342 字
▲Celltrion (068270.KS) = Filed for a change to its European Phase 3 trial of a Darzalex biosimilar
▲Hanmi Semiconductor (042700.KS) = Second-quarter preliminary operating profit rose 51% from a year earlier
▲M&C Solution (484870.KS) = Newly appointed Kim Chul as an outside director and audit committee member at an extraordinary shareholders' meeting
▲Kyungdong City Gas (267290.KS) = Resolved to convene an extraordinary shareholders' meeting on August 21
▲HD Hyundai Heavy Industries (329180.KS) = Changed the termination date of a contract to supply two PCTCs for Europe
▲Kakao = Resolved to sign a naming sponsorship contract for the Seoul Arena complex cultural facility
▲KT (030200.KS) = Decided on a cash dividend of 600 won per share and the disposal of 3,109 treasury shares
▲CMES Robotics (475400.KQ) = Signed a contract to supply robot automation equipment with Suheung
▲SMEC = Signed a contract to supply semiconductor-specialized machine tools with Sail MT
▲Proichon = Transitioned to a co-CEO system led by Kim Young-sun and Lim Yi-bin
▲Estaid = Decided on a 5-to-1 share consolidation
▲ST Pharm = Announced results of a Phase 2 clinical trial for an HIV-1 treatment
▲TLB = Issued a rights offering to existing shareholders worth 133.1 billion won
▲FutureChem = Set the first offering price for its rights offering at 6,570 won
▲Hanmi Semiconductor (042700.KS) = Second-quarter preliminary operating profit rose 51% from a year earlier
▲M&C Solution (484870.KS) = Newly appointed Kim Chul as an outside director and audit committee member at an extraordinary shareholders' meeting
▲Kyungdong City Gas (267290.KS) = Resolved to convene an extraordinary shareholders' meeting on August 21
▲HD Hyundai Heavy Industries (329180.KS) = Changed the termination date of a contract to supply two PCTCs for Europe
▲Kakao = Resolved to sign a naming sponsorship contract for the Seoul Arena complex cultural facility
▲KT (030200.KS) = Decided on a cash dividend of 600 won per share and the disposal of 3,109 treasury shares
▲CMES Robotics (475400.KQ) = Signed a contract to supply robot automation equipment with Suheung
▲SMEC = Signed a contract to supply semiconductor-specialized machine tools with Sail MT
▲Proichon = Transitioned to a co-CEO system led by Kim Young-sun and Lim Yi-bin
▲Estaid = Decided on a 5-to-1 share consolidation
▲ST Pharm = Announced results of a Phase 2 clinical trial for an HIV-1 treatment
▲TLB = Issued a rights offering to existing shareholders worth 133.1 billion won
▲FutureChem = Set the first offering price for its rights offering at 6,570 won
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。